Children with neuroblastoma, a cancer of the nervous system, are often diagnosed once the cancer is already advanced. While survival rates for most childhood cancers have improved significantly...
In the pursuit to cure cancer, scientists have long dreamed of a ‘magic bullet' to eliminate diseased cells without harming healthy tissue. Now researchers at Children’s Cancer Institute have discovered a way to treat the deadly children cancer, neuroblastoma, that increases the chances of killing the cancer, while reducing the short and long term toxic side effects of current therapy.
Australian researchers have developed a new risk scoring system for children with leukaemia based on missing DNA fragments or ‘microdeletions’.
Researchers have been awarded a 3-year $840K Development Grant to test inhibitors of MRP1, a protein which ejects chemotherapy drugs from cancer cells, in a bid to improve patient survival.
Children with most aggressive cancers to benefit from Australian-first personalised medicine clinical trialSeptember 18, 2017
Personalised medicine for childhood cancers in Australia is a step closer thanks to the Zero Childhood Cancer program’s national clinical trial launched today.
Researchers have discovered how a modified natural compound disrupts angiogenesis, the formation of blood vessel networks, in neuroblastoma tumours, stopping them laying down the vital supply lines that fuel cancer growth and spread.
Professor Michelle Haber AM, of Children's Cancer Institute and UNSW, was today announced as a finalist for the 2017 Australian Museum Eureka Prize for Leadership in Innovation and Science, sponsored by CSIRO.
Three grants totalling almost $1.3 million have been awarded to researchers from Children’s Cancer Institute to investigate new treatments for neuroblastoma.
Introducing Paediatrio, an innovative joint venture that will enable NSW to set the national agenda for child health.
The search for improved treatments for children’s cancers, including innovative research into a currently incurable brain cancer, will take a big step forward as the NHMRC announced funding totalling $4.5M for Children’s Cancer Institute.
The Prime Minister presented a cheque today for $20M to support Australia’s single-biggest initiative in childhood cancer research, the Zero Childhood Cancer national child cancer personalised medicine program.
Professor Maria Kavallaris of Children’s Cancer Institute has been inducted as a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).
A ‘breakthrough’ adult leukaemia therapy called venetoclax could successfully target high-risk leukaemia subtypes in infants or children reveals an Australian study published this month, Childhood Cancer Awareness Month, in prestigious US haematology journal Blood.
Thanks to a $1.5M grant from the Australian Cancer Research Foundation (ACRF), the new ACRF Child Cancer Personalised Medicine Centre’s specialised robots can now rapidly test hundreds of treatments for kids with high-risk cancers to guide their care.
Recent advances in drug discovery technology and molecular studies could yield a suite of potential drugs that target cancer’s secret of eternal youth, argue Australian researchers in a Nature Reviews Cancer paper this month.
In the future, simple blood tests for circulating tumour cells or DNA could be an efficient and non-invasive way to track changes in patients with one of childhood’s more common cancers, neuroblastoma.
Children’s Cancer Institute, one of six partners in the Kids Cancer Alliance, was a major recipient of translational research grants from the Cancer Institute NSW.
We are delighted that the Prime Minister has announced today a $20M funding commitment for Australia’s single-biggest initiative in childhood cancer, the Zero Childhood Cancer Program.
Children’s Cancer Institute is proud to share the news that hundreds of Australian children with high-risk cancer will have access to new genome sequencing technologies that could guide their treatment, following the announcement today of substantial Lions Club funding for the Lions Kids Cancer Genome Project – an important new component of the Zero Childhood Cancer Program for diagnosis and treatment of childhood cancer.
Who says you can’t teach an old dog new tricks? It seems drugs that have been around for years can sometimes do something spectacular when applied in a whole new way.
Cancer Council NSW has awarded Children’s Cancer Institute its fourth consecutive 5-year Program Grant to research ways of improving treatments for children with ‘refractory’ acute lymphoblastic leukaemia (ALL) – in other words, children diagnosed with a high-risk subtype of the disease, or who have received treatment and have subsequently relapsed.
Children's Cancer Institute ('the Institute') hereby advises that the Australian Securities and Investments Commission (ASIC) have consented to the resignation of the Institute's auditors, Moore Stephens, effective from the date of the attached notice.
Professor Maria Kavallaris from Children’s Cancer Institute has been recognised as one of ‘The Knowledge Nation 100’ - Australia’s top 100 “visionaries, intellects, founders and game changers” who will help shape the country’s future prosperity.
Two inspiring postdoctoral researchers from Children’s Cancer Institute, Dr Daniel Carter and Dr Duohui (Vincent) Jing, are recipients of the 2015 Balnaves Foundation Young Researcher’s Fund. The Balnaves Foundation, a private philanthropic organisation set up by Neil Balnaves AO in 2006, has awarded each researcher $100,000 to explore uncharted territory in childhood cancer.
Australian scientists have identified a critical molecular ‘feedback loop’ that helps initiate and drive neuroblastoma, a cancer of the nervous system in children that is triggered in embryonal nerve cells.
A team of inspirational child cancer researchers – Professors Glenn Marshall, Michelle Haber and Murray Norris – have been selected as finalists in the Health category of The Australian Innovation Challenge, announced in The Australian newspaper today.
Professor Maria Kavallaris one of The Australian Financial Review and Westpac’s 100 Women of Influence 2015September 24, 2015
Professor Maria Kavallaris, Head of the Tumour Biology & Targeting Program at Children's Cancer Institute and founding Director of the Australian Centre for NanoMedicine at UNSW Australia, has been named one of The Australian Financial Review and Westpac’s 100 Women of Influence 2015.
Children’s Cancer Institute welcomes its inclusion, by the US National Cancer Institute (NCI), in a systematic program of drug evaluation in childhood cancer.
Children’s Cancer Institute and Sydney Children’s Hospital, Randwick (part of The Sydney Children’s Hospitals Network) are proud to announce one of the most exciting childhood cancer research initiatives ever undertaken in Australia, to tackle the most serious cases of infant, childhood and adolescent cancer. Launched today at Children’s Cancer Institute, ‘Zero Childhood Cancer’ gives hope to children with the highest risk of treatment failure or relapse.
The CEO of the NHMRC Professor Anne Kelso, today announced the appointment of Professor Maria Kavallaris, Head of the Tumour Biology & Targeting Program at Children's Cancer Institute, to the Research Committee of the National Health and Medical Research Council (NHMRC).
Today’s passing of the legislation for the Medical Research Future Fund (MRFF) in the Senate has brought hope not just to the Australian health and medical research sector but also to the entire country, according to the Association of Australian Medical Research Institutes (AAMRI).
Children’s Cancer Institute is delighted to announce the strengthening and formalisation of its relationship with Melbourne’s Peter MacCallum Cancer Centre through a Memorandum of Understanding (MoU) that specifies areas of collaboration in cancer research for children and adolescents.
A new Australian study shows that a recently-developed drug, already used safely in adult leukaemia clinical trials1, holds great promise for some children with an aggressive form of cancer known as acute lymphoblastic leukaemia (ALL).
Minister for Health Jillian Skinner and Minister for Medical Research Pru Goward have visited The Children’s Hospital at Westmead to announce the 2015-16 Budget will include $25 million for paediatric research to unlock treatments and cures.
Children’s Cancer Institute is thrilled to announce that our Deputy Director, Professor Murray Norris, has been appointed a Member of the Order of Australia as part of the 2015 Queen’s Birthday Honours List for outstanding achievement and contribution in the field of childhood cancer research.
Townsville based cancer research foundation, The Cure Starts Now (Australia), has granted Children’s Cancer Institute another $100,000 to expand research in to Diffuse Intrinsic Pontine Glioma (DIPG) – the most aggressive and deadly of all childhood cancers.
Children’s Cancer Institute is pleased to announce that our Executive Director, Professor Michelle Haber AM, has been elected as a Fellow of the newly formed Australian Academy of Health & Medical Sciences (AAHMS).
A team led by Children’s Cancer Institute researchers has been awarded a grant by the National Health & Medical Research Council (NHMRC), announced today by the Minister for Health, the Hon Sussan Ley MP, for its innovative work into two of the most aggressive types of childhood cancer.
Children's Cancer Institute's outstanding research work has been recognised by the Cancer Institute NSW's Translational Program Grants, announced yesterday by NSW Minister for Health and Medical Research, The Hon Jillian Skinner MP.
Children’s Cancer Institute researchers have identified a drug as a potential treatment for a particularly aggressive, chemotherapy-resistant type of paediatric leukaemia.
Children’s Cancer Institute is delighted to be one of three recipients of a ground-breaking investment by the state government into paediatric medical research.
The Balnaves Foundation has once again shown its commitment to curing childhood cancer by awarding two aspiring researchers at Children’s Cancer Institute the Balnaves Young Researcher of the Year Award 2014.
Children's Cancer Institute has welcomed the announcement by the Prime Minister and the Minister for Health of a new funding package to see the $20 billion Medical Research Future Fund (MRFF) realised.
Children’s Cancer Institute researchers have identified, for the first time, new properties essential to drug-resistant tumour cells that could revolutionise cancer treatment and reduce the side-effects of chemotherapy.
Children’s Cancer Institute has been awarded a grant of $1.5 million for the establishment of a precision medicine centre. The centre heralds a new era in childhood cancer research and treatment and has the very real potential to substantially improve patient outcomes and survival rates.
Researchers have made an important step towards a 100% survival rate for the most common type of childhood cancer, with the latest findings of a trial for children with relapsed acute lymphoblastic leukaemia confirming the superiority of a chemotherapy drug for treating the disease.
Researchers from Children’s Cancer Institute have uncovered a potential new treatment for acute lymphoblastic leukaemia – the most common form of childhood cancer.
Children’s Cancer Institute is thrilled to announce that our Executive Director, Professor Michelle Haber AM, has been awarded the Premier’s Award for Outstanding Cancer Researcher of the Year 2014, in recognition of her significant contribution to research into childhood cancer.
Researchers at Children’s Cancer Institute have uncovered, for the first time, another gene linked to the cause of one of the most aggressive forms of childhood cancer – that could provide new targets for cancer therapy and change the way we treat the disease.
Children’s Cancer Institute is extremely proud to announce that His Excellency General the Honourable Sir Peter Cosgrove AK MC (Retd), Governor-General of the Commonwealth of Australia, has become a Patron for our organisation.
Brian and Glenda Byrne have endured the almost unbelievable heartbreak of losing three of their four sons - in completely unrelated incidents. Following the death of their youngest son, Kieran, from a rare form of childhood cancer, their only surviving son, Brendan, received harrowing news about his own daughter, Matilda. Watch as the family tells its fascinating story.
Internationally renowned medical research organisation, Children’s Cancer Institute, is this year celebrating 30 years since its lab doors first opened. The milestone was officially launched today at the Institute’s Annual General Meeting.
As we celebrate 30 years of dedicated medical research into childhood cancer, we are very excited to be at the forefront of a new era in childhood cancer treatment: personalised medicine.
“While it’s tough knowing there are children out there suffering with the disease, staying positive isn’t that hard. The courage of children, and their parents, is an incredible inspiration.” - Dr Daniel Carter
On Friday 4 April, close to 100 keen cyclists put foot to pedal at Sydney Motor Sport Park, Eastern Creek in an incredible display of endurance to cure kids’ cancer.
Children’s Cancer Institute is proud to announce its personalised medicine program for children with cancer as a key partner of the newly-funded Cancer Therapeutics Cooperative Research Centre (CTx).
Australian researchers at Children's Cancer Institute and Sydney Children's Hospital are part of an international research collaboration that has discovered a genetic link specific to the risk of childhood leukaemia.
Children's Cancer Institute researcher, Dr Orazio Vittorio, was awarded the inaugural Kids' Cancer Project award at the NSW Premier's Awards for Outstanding Cancer Research for research looking at the anti-cancer properties of an antioxidant.
Researchers at Children's Cancer Institute have discovered that beta-blockers, traditionally used in the treatment of hypertension, can increase the effectiveness of chemotherapy in childhood cancers, such as neuroblastoma.
Researchers at Children's Cancer Institute have shown that a new antibody-based drug has the potential to improve the survival rate for children who relapse from one of the most common types of paediatric blood cancers: acute lymphoblastic leukaemia.